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Extrapolation of Animal
Carcinogenicity Data:
Limitations and Pitfalls
by M. D. Hogan*
Laboratory-generated animal bioassay data often serve as the basis for estimating potential
human cancer risk. However, there is no single procedure that has been universally accepted as
the method ofchoice for extrapolating experimentally observed results to the low exposure levels
that are generally ofpublic health concern. All ofthe models proposed to date sufferfromvarious
limitations. Therefore, the most prudent approach may be to rely primarily on the more
conservative procedures such as linear extrapolation until a better understanding of the
biological mechanisms underlying the process of carcinogenesis is attained.
In addition tothe choice of an extrapolation model, there are avariety ofother factors, such as
the incorporation ofbackground cancer rates, the potential for synergistic reactions, differential
pharmacokinetic effects and differences in exposure regimen, that can have a significant bearing
on the extrapolation of animal carcinogenicity data to man.
Introduction
Due to a lack of meaningful epidemiologic data,
many estimates ofthe human health risk posed by
environmental exposures to potential carcinogens
are based onresults derived fromlaboratory animal
experimentation. The primary source ofthis exper-
imental data is the lifetime cancer screening study
or bioassay.
Typically, the investigator who deals with cancer
risk assessment is interested in excess risks of the
order 104 to 107 or even less. Animal bioassays
sensitive to such low levels of response would
obviously require a study population of enormous
and totally impractical size. Therefore, the investi-
gator who wants to assess potential human cancer
risk using laboratory-based data must be able to
extrapolate his experimentally observed results to
exposure levels of public health concern.
Since the investigator often has no empirical
knowledge about the behavior ofthe test chemical's
underlyingdose-response curve, heisusuallyforced
to rely on some form of mathematical model to
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characterize the unknown relationship between
exposure and tumor response, especially in the
low-dose region of interest. To date, no single
model has been accepted as the most appropriate
for low-dose extrapolation. A wide variety of
approaches have been proposed, including models
that attempt to establish an upper bound on the
unknown cancer risk, tolerance distribution mod-
els, models that presumably reflect a general mech-
anistic process hypothesized to underlie tumor
onset and models based on time to tumor occur-
rence. Each of these approaches is recognized as
having its own inherent limitations.
Extrapolation Models
Linear Model
The (no threshold) linear model is the simplest
and certainly one of the most commonly employed
of the low-dose extrapolation techniques. Under
this model it is assumed that the probability of
developing cancer is directly proportional to the
administered dose at least over some "low-dose"
region. Therefore, if Pt represents the observed
proportion of animals who developed tumors afterbeing exposed to the test chemical at dose level d,
then the estimated risk corresponding to any dose
level d' within the range [O,d] is given by
P' = (PtId)d'
If the dose range [O,d] falls within the convex
portion of the true dose-response curve, then it is
clear that p' will actually be an upper bound on the
unknownunderlying cancerrisk. Furthermore, some
investigators (1) have advocated the incorporation
of an additional protective factor in the estimation
process by replacing Pt with some upper confidence
limit on Pt determined from binomial distribution
theory.
While this procedure obviously has a great deal
of intuitive appeal, it is not immune to criticism.
Forexample, there areundoubtedlymanyinstances
in which its use leads to an unduly conservative
estimate of the probability of developing a tumor.
On the other hand, if the experimental dose range
falls outside the convex portion of the underlying
dose-response curve, the projected risk obtained
through linearextrapolation couldsignificantly under-
estimate the true likelihood of tumor onset. In the
absence of prior knowledge about the test chemi-
cal's behavior, the experimental data may not be
sufficient to determine whether the linear extrapo-
lation is likely tounderestimate oroverestimate the
actual risk.
Tolerance Distribution Models
The next major class of models employed in low-
dose extrapolation is known as the tolerance distri-
bution models. This title reflects the underlying
model assumptions (2,3) that every individual (ani-
mal) inthe studypopulation has his/her ownlevel of
tolerance to or threshold for the exposure under
investigation, thatthesethresholdlevelsvaryamong
individual members of the study population and
thatthe distribution ofthesetolerance levels canbe
described in terms of some cumulative probability
distribution function F. Given these assumptions,
the probability P(d) of developing a tumor as a
result of exposure to a dose d of the chemical of
interest is equivalent to the probability of an indi-
vidual having a threshold level of d or less, i.e.,
P(d) = F(a + B log d)
IfF is assumed to be the cumulative normal distri-
bution, then P(d) is the log-probit model long em-
ployedbybiologistsinmedianlethaldoseestimation.
Alternativemodels, suchasthelogisticand extreme
value models, can be obtained by adopting other
distributional forms for F (3).
Theuse ofthelog-probit modelinlow-dose extrap-
olation of carcinogenicity data was pioneered by
Mantel and Bryan (4,5). They proposed that an
upper bound on the dose associated with some
preselected "acceptable" level of cancer risk could
be estimated by extrapolating from an upper confi-
dence limit on the proportion of experimental ani-
mals exhibiting tumors (plotted on a probit versus
log dose scale) along a dose-response line with a
fixed slope ofone. Their choice ofa slope ofone was
based on empirical observations which suggested
that this value would typically lead to a conserva-
tive estimate of the dose corresponding to the
"acceptable" risk level.
While the Mantel-Bryan procedure was initially
regarded by many investigators as a reasonable
technique for estimating the low-dose cancer risk,
subsequent research has enumerated a variety of
deficiencies associated withits applicationthathave
raised serious doubts (2,3,6) about its continued
utility. For example, even though the Mantel-
Bryan procedure was supposedly designed to gen-
erate aconservative estimate ofthe dose associated
with some predetermined "acceptable" level ofrisk,
the log-probit modelupon which it is based tends to
approach the origin more rapidly than any of the
alternative models employed in low-dose extrapola-
tion. Thus, in the low-dose region, the Mantel-
Bryan procedure can produce "safe-dose" estimates
that are orders of magnitude higher than those
generated by competingtechniques (3). In addition,
there is no mechanistic model for carcinogenesis
that is reasonably approximated by a log-probit
distribution. Finally, the Mantel-Bryan procedure
employs Abbott's correction factor (4) to take back-
ground cancer incidence into account, which has
certain implications about the stochastic indepen-
dence ofbackground and chemically induced tumors
that may not hold in general.
"Hit" Models
From a mechanistic point ofview the most inter-
esting class oflow-dose extrapolation procedures is
made up of what are commonly known as "hit"
models, a name that refers to a hypothesized pro-
cess of carcinogenesis upon which they are based.
Essentially, this process depicts cancer originating
as a malignant cell that has undergone a finite
number of somatic mutations or incurred a finite
number of hits or receptor interactions with the
study chemical. [This mechanistic representation of
carcinogenesis has been discussed in some detail
(7).] Includedinthis categoryare the one-hitmodel,
P(d) = 1 - exp {- Xd}
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where X is an unknown model parameter and Xd is
the expected number of hits at dose d; the multi-
stage model,
P(d) = 1-exp{-(XO +X1d +X2d2 + * + kdk)}
where the Xiareunknown, nonnegative modelparam-
eters and k corresponds to the number of transi-
tional events or stages in the carcinogenic process;
and the Gamma multi-hit model,
P(d) = fod[F(k)]l1k tkl1 exp {-At}dt
where A is anunknown model parameter and F(k) is
the standard gamma function.
The one-hit model, which assumes that the carci-
nogenic process can be initiated after a single cellu-
lartransition has occurred, is certainly the simplest
ofthe various hit models to apply. It often produces
estimates that are quite similar to those obtained
with the linear model, but it has the advantage of
using all ofthe experimental data simultaneously in
the estimation of its model parameter. However,
sincetheone-hitmodelinvolvesonlyasingleunknown
parameter, it does not always generate an adequate
fit to the experimental observations.
The multistage model in its various formulations
has been, perhaps, the most intensely researched
and widely employed of the different hit models.
Complex computer packages have been developed
for fitting this model to experimental data, and
many regulatory bodies regard it as one of the
standard tools of risk estimation and assessment.
Nevertheless, a number of objections have been
raised against its unrestricted usage. Since it often
behaves like a simple linear model in the low-dose
region, it tends to be one ofthe more conservative
of the currently popular extrapolation procedures.
Furthermore, the multistage model asitistypically
applied assumes that background tumor incidence
and the chemically induced carcinogenesis are basi-
cally additive components of the same underlying
process; and some investigators questionthe appro-
priateness of this assumption (8).
The last of the models to be considered in this
category, theGammamulti-hitmodel, canbethought
ofas an extension ofthe simple one-hit model (3) in
which at least k hits are required to initiate tumor
development. While this procedure has been rec-
ommended by the Food Safety Council (8) foruse in
low-dose cancer risk estimation, a recent, detailed
assessment (9) of the analyses presented in the
Council's report indicated that there are a number
of serious practical problems associated with its
employment. For instance the Gamma multi-hit
model canproducerelatively high projections ofthe
background incidence rate even when no tumors
areobserved amongtheexperimentalcontrols. This,
in turn, can lead to unreasonably high estimates of
the "safe" dose corresponding to some predeter-
mined "acceptable" level ofrisk. Onthe otherhand,
since the Gamma multi-hit model allows for hyper-
linearity, it can also generate unrealistically low
safe-levelestimates. Then, likethelog-probitmodel,
it treats the induced tumor rate as being indepen-
dent of background. Although this assumption is
very difficult to verify empirically, it can have a
tremendous impact on the magnitude of the low-
dose risk estimate.
Time to Tumor Models
Now, each of the extrapolation models consid-
ered above assumes that the basic experimental
data will be limited to tumor incidence over time.
However, in some large-scale studies there may
alsobeusefulinformationavailable ontimetotumor
occurrence or observance. Given such data, it may
be possible to fit a mathematical model that depicts
a more complex relationship between dose, tumor
incidence, and age at which the tumor is detected,
and then to use this model to develop estimates of
the low-dose risk. Among the various procedures
that have been applied to these types of data are
the log-normal (1), Weibull (1), Armitage-Doll Mul-
tistage (10) and Hartley-Sielken (11) models.
Unfortunately, the experimental data obtained
from the typical cancer bioassay will often not be of
sufficient sensitivity or quantity to allow an inves-
tigator to distinguish between the "fits" provided
by competing models (10,12). (In fact in many
instances time to tumor information may not even
be collected.) Yet, as with the quantal response
models, the selection of a specific time to tumor
model can have a very significant impact on the
estimate of low-dose risk. On the other hand, the
existence ofa substantial quantity ofbioassay time
to tumor information may not ensure satisfactory
modeling. Forexample, preliminary analyses ofthe
massive data set generated by the NCTR EDO1
study (13) of 24,000 mice exposed to the known
carcinogen 2-AAF suggest that even the relatively
sophisticated Armitage-Doll and Hartley-Sielken
time to tumor models do not adequately describe
the experimental results (14).
Even this briefreview ofcarcinogenesis extrapo-
lation models clearly indicates that there is no
general agreement as to the method of choice for
low-dose risk estimation. Given the various short-
comings associated with each of the procedures
under discussion, it is difficult to decide whether
these models are really reflecting some underlying
biological mechanism or merely acting as curve-
fitting devices. [The recently expressed doubts (15)
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sis, a role that underlies the different hit models,
contribute to this uncertainty.] Until additional
research confirms the biological appropriateness of
these various models, the most prudent approach
from a public health viewpoint may be to rely
heavily on the more conservative, simplistic ap-
proaches tolow-dose riskestimationlikethat offered
by the linear model.
To obtain an empirical estimate ofthe variability
associated with the selection of this (or any other)
extrapolation model, it may be worthwhile to con-
sider the point estimates generated by other extrap-
olation models as well as the magnitude of the
range intheseprojections. (Ifthis exercise is under-
taken, the log-probit model should probably be
excluded from consideration because ofits potential
for underestimating the true risk.)
Other Considerations
There are a number of other issues besides the
selection of a mathematical model that need to be
considered when extrapolatinganimal carcinogenic-
ity data. As has already been indicated, deciding
whether to treat the background and study chemi-
cal exposures as independent or additive phenom-
ena can have a very significant impact on the low-
dose risk estimates. It is well known (16) that if
background can be regarded as additive in a mech-
anistic sense, then, quite generally, the relation-
ship between dose and response will be essentially
linear in the low-dose region. However, recent
results obtained by Hoel (17) imply that if back-
ground is not totally independent of the chemical
exposure under study, then low-dose linearity will
tend to prevail regardless ofthe model selected for
extrapolation. The significance of this finding is
obvious when one considers the likelihood that the
assumption oftotalindependence can bejustified on
biological grounds for any given chemical.
Another issue that can have important bearing
on the estimation of low-dose risk is the relation-
ship between the externally administered dose and
the concentration of active material reaching the
target tissue or cell. While the preceding discussion
of the various extrapolation models essentially
assumed that the fate of the chemical under study
does not depend on dose, this assumption will not
always be appropriate. One reason for the possible
existence of dose dependency is that many poten-
tially carcinogenic compounds require metabolic acti-
vation, which is an enzyme-mediated process. Con-
sequently, theamountofreactivemetabolitereaching
the target tissue will not necessarily be propor-
porating pharmacokinetic considerations into the
tional to the administered dose. The value ofincor-
extrapolation process has been demonstrated by
both Gehring et al. (18,19) and by Anderson et al.
(20). Each investigator reanalyzed previously pub-
lished data on vinyl chloride and found that a
significantly improved fit to the experimental data
was obtained for either the log-probit or multistage
modelwhenthepharmacokinetics ofthe studychem-
ical were taken into consideration.
Investigators can also be confronted with the
problem of deciding what is the most appropriate
way to use continuous dosing, lifetime bioassay
data to estimate human cancer risk associated with
an exposure ofmuch shorter duration. Whittemore
(21) and Day and Brown (22) have investigated the
general issue of lifetime versus less than lifetime
exposure assuminganunderlyingmultistagemodel.
While both studies provided insight into the rela-
tionship amongdifferent temporal patterns ofexpo-
sure, the stage ofthe carcinogenic process effected
by the exposure in question, and the resulting
cancer risk, the issue is still far from being fully
resolved.
Another issue than can affect low-dose extrapola-
tion and that is also far from being completely
resolved is the problem of reconciling the single-
agent exposure regimen of the standard animal
bioassay with the simultaneous multiple exposure
environment of man. Usually, very little is known
about the potential synergistic/antagonistic effects
of the study compound when given in combination
with other agents. Therefore, the issue is often
ignored; or, at most, simple additivity is assumed.
Finally, any attempt to extrapolate animal can-
cer data to man must ultimately deal with the issue
of species scale-up. Many investigators feel that
this is an even more difficult problem to address
than low-dose extrapolation. Species extrapolation
will obviously be complicated ifthere are significant
differences between the experimental test species
and man with respect toimportant pharmacokinetic
effects such as metabolism and excretion. In addi-
tion, temporal, size, population structure, and expo-
sure regimen differences can also complicate the
scaling-up process.
In spite of all the limitations and pitfalls associ-
ated with the extrapolation of animal carcinogenic-
ity data, however, the process is still a more rea-
sonable procedure forestimatinghuman cancerrisk
than the traditional safety factor approach which it
has supplanted. Extrapolation can at least be used
to rank-order priorities in addressing the possible
carcinogenic hazards posed by various environmen-
tal exposures and to develop a rough estimate of
the health impact of such exposures.
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